Phase 2 study
Recruiting Phase 2
This trial at a glance
Where this trial is running
| Site | City | State or country | Status at this site |
|---|---|---|---|
| Scientia Clinical Research Ltd | Randwick | NSW | Terminated |
voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice
Who can join
The official eligibility criteria
Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.
Inclusion Criteria:
* Signed informed consent.
* Age ≥ 18 years.
* Life expectancy of \> 3 months, in the opinion of the investigator.
* Ability to take oral medications and willing to record daily adherence to sotorasib through the use of a written diary.
* Participant is currently receiving treatment with sotorasib alone or in combination therapy in an Amgen-sponsored trial that has met its endpoints or otherwise will be stopping (also referred to as parent study) and are continuing to receive clinical benefit in the opinion of the investigator.
* For a participant on combination therapy in their parent study, treatment with other anti-cancer therapies is allowed provided it matches the parent study.
* Eastern Cooperative Oncology Group Performance Status of ≤ 2.
Exclusion Criteria:
* Participant had permanently discontinued from sotorasib study treatment in the parent study before the parent study's completion.
* Ongoing, unresolved toxicity requiring interruption of sotorasib treatment at the time of the termination of the parent study.
* Local access to commercially available investigational product(s) at no cost to the participant as permitted by local/country regulation.
* Anticipated toxicities of sotorasib study treatment outweigh the clinical benefit to the participant in the opinion of the investigator.
* Participant unlikely to be able to complete all protocol-required procedures, restrictions and requirements, in the judgment of the individual and investigator.
* Significant uncontrolled concomitant disease that could affect compliance with protocol procedures or interpretation of results or that pose a risk to participant safety, in the opinion of the investigator.
* Female participants of childbearing potential unwilling to use protocol-specified method of contraception during treatment and for an additional:
* 7 days after the last dose of sotorasib.
* 2 months after the last dose of panitumumab.
* Female participants who are breastfeeding or who plan to breastfeed while on study through:
* 7 days after the last dose of sotorasib.
* 2 months after the last dose of panitumumab.
* Female participants planning to become pregnant while on study through:
* 7 days after the last dose of sotorasib.
* 2 months after the last dose of panitumumab.
* Female participants of childbearing potential with a positive pregnancy test assessed at screening or day 1 by a highly sensitive urine or serum pregnancy test.
* Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 7 days after the last dose of sotorasib.
* Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment and for an additional 7 days after the last dose of sotorasib.
* Male participants unwilling to abstain from donating sperm during treatment and for an additional 7 days after the last dose of sotorasib.
Dates on the record
Results, publications and the official record
- No results are posted on the official record yet.
- No publications are listed on the official record yet.
- Official record and contacts on ClinicalTrials.gov – contact details for each site are kept there, and are not copied onto this page.
Sources and dates
- ClinicalTrials.gov – the record this page reformats
- ClinicalTrials.gov processing date: 23 July 2026.
- This page last checked by Voxsanity: 11 October 2026.
Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.
Not medical advice.
Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.
Letter for your doctor
A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.